UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Human Rights and Global Governance: Power Politics Meets International Justice

Meyer, William H

1st edition., 2019

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Factors in Metastatic Rhabdomyosarcomas: Results of a Pooled Analysis From United States and European Cooperative Groups

Journal of clinical oncology, 2008-05, Vol.26 (14), p.2384-2389

2008

Link zum Volltext

Verfügbarkeit prüfen

Analysis of Prognostic Factors in Patients With Nonmetastatic Rhabdomyosarcoma Treated on Intergroup Rhabdomyosarcoma Studies III and IV: The Children's Oncology Group

Journal of clinical oncology, 2006-08, Vol.24 (24), p.3844-3851

2006

Link zum Volltext

Verfügbarkeit prüfen

Results of the Intergroup Rhabdomyosarcoma Study Group D9602 Protocol, Using Vincristine and Dactinomycin With or Without Cyclophosphamide and Radiation Therapy, for Newly Diagnosed Patients With Low-Risk Embryonal Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group

Journal of clinical oncology, 2011-04, Vol.29 (10), p.1312-1318

2011

Link zum Volltext

Verfügbarkeit prüfen

Vincristine, Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803

Journal of clinical oncology, 2009-11, Vol.27 (31), p.5182-5188

2009

Link zum Volltext

Verfügbarkeit prüfen

Testing Theories of Labor Rights and Development

Human rights quarterly, 2015-05, Vol.37 (2), p.414-438

Meyer, William H.

2015

Link zum Volltext

Verfügbarkeit prüfen

Gene Expression Profiling for Survival Prediction in Pediatric Rhabdomyosarcomas: A Report From the Children's Oncology Group

Journal of clinical oncology, 2010-03, Vol.28 (7), p.1240-1246

2010

Link zum Volltext

Verfügbarkeit prüfen

Maintenance chemotherapy in rhabdomyosarcoma: the new standard of care

The lancet oncology, 2019-11, Vol.20 (11), p.1476-1477

Meyer, William H

2019

Link zum Volltext

Verfügbarkeit prüfen

Two Consecutive Phase II Window Trials of Irinotecan Alone or in Combination With Vincristine for the Treatment of Metastatic Rhabdomyosarcoma: The Children's Oncology Group

Journal of clinical oncology, 2007-02, Vol.25 (4), p.362-369

2007

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Significance and Tumor Biology of Regional Lymph Node Disease in Patients With Rhabdomyosarcoma: A Report From the Children's Oncology Group

Journal of clinical oncology, 2011-04, Vol.29 (10), p.1304-1311

2011

Link zum Volltext

Verfügbarkeit prüfen

Improving Outcomes for Patients With Pulmonary Metastatic Ewing Sarcoma

Journal of clinical oncology, 2019-12, Vol.37 (34), p.3173-3175

Meyer, William H.

2019

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase II Window Trial of Two Schedules of Irinotecan With Vincristine in Patients With First Relapse or Progression of Rhabdomyosarcoma: A Report From the Children's Oncology Group

Journal of clinical oncology, 2010-10, Vol.28 (30), p.4658-4663

2010

Link zum Volltext

Verfügbarkeit prüfen

Alveolar rhabdomyosarcoma has superior response rates to vinorelbine compared to embryonal rhabdomyosarcoma in patients with relapsed/refractory disease: A meta‐analysis

Cancer medicine (Malden, MA), 2023-05, Vol.12 (9), p.10222-10229

2023

Link zum Volltext

Verfügbarkeit prüfen

The significance of margins in pediatric Non‐Rhabdomyosarcoma soft tissue sarcomas: Consensus on surgical margin definition harmonization from the INternational Soft Tissue SaRcoma ConsorTium (INSTRuCT)

Cancer medicine (Malden, MA), 2023-05, Vol.12 (10), p.11719-11730

2023

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Factors and Clinical Outcomes in Children and Adolescents With Metastatic Rhabdomyosarcoma—A Report From the Intergroup Rhabdomyosarcoma Study IV

Journal of clinical oncology, 2003-01, Vol.21 (1), p.78-84

2003

Link zum Volltext

Verfügbarkeit prüfen

Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children's Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force

Journal of clinical medicine, 2021-04, Vol.10 (7), p.1416

2021

Link zum Volltext

Verfügbarkeit prüfen

Assessment of Response to Induction Therapy and Its Influence on 5-Year Failure-Free Survival in Group III Rhabdomyosarcoma: The Intergroup Rhabdomyosarcoma Study-IV Experience—A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group

Journal of clinical oncology, 2007-11, Vol.25 (31), p.4909-4913

2007

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Significance of Tumor Response at the End of Therapy in Group III Rhabdomyosarcoma: A Report From the Children's Oncology Group

Journal of clinical oncology, 2009-08, Vol.27 (22), p.3705-3711

2009

Link zum Volltext

Verfügbarkeit prüfen

Regarding Beau

Journal of clinical oncology, 2016-08, Vol.34 (22), p.2669-2670

Meyer, William H

2016

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase II Trial of Bevacizumab or Temsirolimus in Combination With Chemotherapy for First Relapse Rhabdomyosarcoma: A Report From the Children's Oncology Group

Journal of clinical oncology, 2019-11, Vol.37 (31), p.2866-2874

2019

Link zum Volltext

Verfügbarkeit prüfen

Human Rights and Global Governance: Power Politics Meets International Justice

William H. Meyer

2019

Link zum Volltext

Verfügbarkeit prüfen

Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group

Journal of clinical oncology, 2016-01, Vol.34 (2), p.117-122

2016

Link zum Volltext

Verfügbarkeit prüfen

The treatment approach to pediatric non-rhabdomyosarcoma soft tissue sarcomas: a critical review from the INternational Soft Tissue SaRcoma ConsorTium

European journal of cancer (1990), 2022-07, Vol.169, p.10-19

2022

Link zum Volltext

Verfügbarkeit prüfen

Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial

The lancet oncology, 2020-08, Vol.21 (8), p.1110-1122

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.312

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.082)
Mit Volltextzugriff
(1.131)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

Human Rights and Global Governance: Power Politics Meets International Justice

Prognostic Factors in Metastatic Rhabdomyosarcomas: Results of a Pooled Analysis From United States and European Cooperative Groups

Analysis of Prognostic Factors in Patients With Nonmetastatic Rhabdomyosarcoma Treated on Intergroup Rhabdomyosarcoma Studies III and IV: The Children's Oncology Group

Vincristine, Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803

Testing Theories of Labor Rights and Development

Gene Expression Profiling for Survival Prediction in Pediatric Rhabdomyosarcomas: A Report From the Children's Oncology Group

Maintenance chemotherapy in rhabdomyosarcoma: the new standard of care

Two Consecutive Phase II Window Trials of Irinotecan Alone or in Combination With Vincristine for the Treatment of Metastatic Rhabdomyosarcoma: The Children's Oncology Group

Prognostic Significance and Tumor Biology of Regional Lymph Node Disease in Patients With Rhabdomyosarcoma: A Report From the Children's Oncology Group

Improving Outcomes for Patients With Pulmonary Metastatic Ewing Sarcoma

Randomized Phase II Window Trial of Two Schedules of Irinotecan With Vincristine in Patients With First Relapse or Progression of Rhabdomyosarcoma: A Report From the Children's Oncology Group

Alveolar rhabdomyosarcoma has superior response rates to vinorelbine compared to embryonal rhabdomyosarcoma in patients with relapsed/refractory disease: A meta‐analysis

The significance of margins in pediatric Non‐Rhabdomyosarcoma soft tissue sarcomas: Consensus on surgical margin definition harmonization from the INternational Soft Tissue SaRcoma ConsorTium (INSTRuCT)

Prognostic Factors and Clinical Outcomes in Children and Adolescents With Metastatic Rhabdomyosarcoma—A Report From the Intergroup Rhabdomyosarcoma Study IV

Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children's Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force

Assessment of Response to Induction Therapy and Its Influence on 5-Year Failure-Free Survival in Group III Rhabdomyosarcoma: The Intergroup Rhabdomyosarcoma Study-IV Experience—A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group

Prognostic Significance of Tumor Response at the End of Therapy in Group III Rhabdomyosarcoma: A Report From the Children's Oncology Group

Regarding Beau

Randomized Phase II Trial of Bevacizumab or Temsirolimus in Combination With Chemotherapy for First Relapse Rhabdomyosarcoma: A Report From the Children's Oncology Group

Human Rights and Global Governance: Power Politics Meets International Justice

Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group

Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group

The treatment approach to pediatric non-rhabdomyosarcoma soft tissue sarcomas: a critical review from the INternational Soft Tissue SaRcoma ConsorTium

Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial

Suchergebnisse filtern